Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses contraceptive options for adolescent girls, highlighting potential recommendations and contraindications, and reports no new clinical findings.

This study found that the GGC repeat length significantly influenced testosterone levels in oral contraceptive users from high-risk breast cancer families, and homozygosity for short alleles may be linked to increased breast cancer risk.

This chapter reviews botanical treatments for polycystic ovary syndrome, discussing potential benefits but presenting no new clinical results; it emphasizes the use of botanicals for managing symptoms like anovulation, insulin resistance, and inflammation.

This meta-analysis reported that dienogest and combined oral contraceptives had comparable efficacy and tolerability for endometriosis treatment, with therapeutic choice suggested to be based on patient preference and clinical history.

This review discusses antiandrogen therapy for polycystic ovary syndrome, focusing on strategies to manage excessive androgen secretion, but it reports no new clinical results.

This review discusses potential benefits of adding bioidentical progesterone to gender-affirming treatment for trans women and reports no new clinical results; it calls for further research to confirm efficacy and safety.

This study found that baricitinib, a selective Janus kinase inhibitor, led to significantly improved scalp coverage in alopecia areata patients over 36 weeks compared to placebo, though adverse effects like acne and urinary tract infections were reported.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This article discusses the use of oral contraceptives for treating hyperandrogenism in women, reporting improvement in most patients, especially in reducing new hair growth, but presents no new clinical findings.

Bicalutamide may take longer to work for female hair loss, and higher doses might be needed.

This abstract does not provide any research results; it outlines website navigation and access instructions for the JAMA network.

This study found that while the carboplatin-paclitaxel regimen for advanced lung cancer is more affordable than newer treatments and maintains a good performance status, it significantly increases risks of alopecia and peripheral neuropathy.

This study found that cyclin-dependent kinase 4/6 inhibitors used for metastatic breast cancer caused alopecia resembling androgenetic alopecia, negatively impacting patients' quality of life, but topical minoxidil showed potential for improvement.

Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.

In this study, cyproterone acetate with ethinyl estradiol effectively treated acne, hirsutism, and alopecia in women, with the highest success in acne and rare side effects similar to estrogen contraceptives.

This review examines androgen status in male and female obesity and its influence on the metabolic syndrome, but reports no new clinical results.

This study found that ALRN-6924 effectively protected human hair follicles from cyclophosphamide-induced damage in an ex vivo setting, suggesting it may reduce both acute and permanent chemotherapy-induced alopecia.

This study found that combining a GnRH agonist with a low-dose oral contraceptive was more effective in treating hirsutism than either agent alone and prevented hypoestrogenic side effects.

Among cultured sebocytes, this study found that bilobetin significantly inhibited lipid production induced by IGF-1, suggesting potential for use in acne treatment.

The treatment slightly increased hair growth and was safe for most women.

This study found that cucurbitacin I from bitter melon most effectively inhibited the growth of lung cancer cells and promoted hair cell growth in cell cultures.

This study found that treatment with cyproterone acetate was generally successful for women with virilizing features, showing improved results in younger women and those with adrenal hirsutism, despite some side effects.

This study observed that adolescents with alopecia areata receiving ritlecitinib 50 mg daily showed notable hair regrowth over three years, as seen in both clinician- and patient-reported outcomes. However, the decreased number of participants at later stages limits the findings.

This announcement discusses the recent FDA approval of baricitinib for treating severe alopecia areata in adults and reports no new clinical results.

This abstract introduces TrichoFoam™, a new foaming vehicle for compounding pharmacies, designed to be a gentle, non-irritating option for alopecia treatment, acknowledging that current topical treatments are limited and oral products may cause adverse effects.

This study found that photobiomodulation may accelerate hair regrowth one month after chemotherapy in breast cancer patients, but no significant differences were observed at two and three months post-therapy.

This study evaluated the long-term safety of ritlecitinib in adolescents with alopecia areata and found it to be well-tolerated without new safety concerns over approximately five years, with common adverse events including positive SARS-CoV-2 tests, acne, headache, and nasopharyngitis.

In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.

This study suggests that using cholesterol-free liposomes, specifically PPD-Lip, as a delivery system with dutasteride may enhance the treatment of androgenetic alopecia by promoting hair regrowth in mice models.

This study observed that patients with alopecia areata taking ritlecitinib reported higher satisfaction with hair growth after 24 and 48 weeks compared to those taking a placebo, aligning with improvements in hair growth noted by doctors.